Provention Bio Inc (PRVB) Expected to Announce Earnings of -$0.28 Per Share

Share on StockTwits

Wall Street analysts expect Provention Bio Inc (NASDAQ:PRVB) to report earnings per share of ($0.28) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Provention Bio’s earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.30). Provention Bio reported earnings of ($1.05) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 73.3%. The business is expected to announce its next earnings results on Monday, August 12th.

On average, analysts expect that Provention Bio will report full-year earnings of ($1.11) per share for the current year, with EPS estimates ranging from ($1.24) to ($0.98). For the next financial year, analysts expect that the business will report earnings of ($0.94) per share, with EPS estimates ranging from ($1.09) to ($0.78). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Provention Bio.

Provention Bio (NASDAQ:PRVB) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.11).

PRVB has been the topic of a number of research reports. Zacks Investment Research lowered shares of Provention Bio from a “buy” rating to a “hold” rating in a research note on Thursday, May 16th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Provention Bio in a research note on Thursday, April 25th. Svb Leerink started coverage on shares of Provention Bio in a research note on Friday, February 22nd. They issued an “outperform” rating and a $6.00 target price on the stock. Finally, Leerink Swann initiated coverage on shares of Provention Bio in a research note on Friday, February 22nd. They issued an “outperform” rating on the stock.

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc purchased a new stake in shares of Provention Bio in the third quarter valued at $2,859,000. Vanguard Group Inc. purchased a new position in Provention Bio in the 3rd quarter worth about $2,859,000. Lido Advisors LLC purchased a new position in Provention Bio during the 4th quarter valued at about $47,000. Silverleafe Capital Partners LLC purchased a new position in Provention Bio during the 1st quarter valued at about $46,000. Finally, Alambic Investment Management L.P. purchased a new position in Provention Bio during the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 1.74% of the company’s stock.

Shares of NASDAQ:PRVB opened at $3.77 on Tuesday. Provention Bio has a 52 week low of $1.52 and a 52 week high of $8.00. The firm has a market capitalization of $141.97 million and a P/E ratio of -3.17.

About Provention Bio

Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.

Featured Story: What type of investment options does a Roth IRA provide?

Get a free copy of the Zacks research report on Provention Bio (PRVB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ooma Inc  CFO Sells $64,302.06 in Stock
Ooma Inc CFO Sells $64,302.06 in Stock
Norman Gennaro Sells 752 Shares of Zendesk Inc  Stock
Norman Gennaro Sells 752 Shares of Zendesk Inc Stock
Richard Rappaport Sells 3,000 Shares of Skechers USA Inc  Stock
Richard Rappaport Sells 3,000 Shares of Skechers USA Inc Stock
Sailpoint Technologies Holdings Inc  Director Sells $80,000.00 in Stock
Sailpoint Technologies Holdings Inc Director Sells $80,000.00 in Stock
James Franklin Sells 50,000 Shares of Ur-Energy Inc.  Stock
James Franklin Sells 50,000 Shares of Ur-Energy Inc. Stock
Gordon R. Bernard Sells 8,876 Shares of Cumberland Pharmaceuticals, Inc.  Stock
Gordon R. Bernard Sells 8,876 Shares of Cumberland Pharmaceuticals, Inc. Stock


© 2006-2019 Ticker Report